Form 4: Verve Therapeutics CFO Allison Dorval Receives Stock Options and Restricted Stock Units

Verve Therapeutics' Chief Financial Officer, Allison Dorval, was granted stock options and restricted stock units on January 8, 2025, according to a recent SEC filing.

Summary

• Allison Dorval, the Chief Financial Officer of Verve Therapeutics, received stock options and restricted stock units on January 8, 2025.
• The stock options include 258,000 shares with a strike price of $6.01, vesting over time, and 75,000 shares that vest immediately if the stock price reaches $20 for 15 consecutive days within two years.
• Additionally, 45,000 restricted stock units were granted, vesting in three equal annual installments starting April 1, 2026.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which are generally viewed positively as they align management interests with shareholders. There are no negative aspects to the document.

Positives

• The stock options and restricted stock units provide an incentive for the CFO to contribute to the company's success.
• The vesting schedule of the options and restricted stock units aligns the CFO's interests with those of the shareholders.
• The performance-based vesting of 75,000 stock options encourages the CFO to drive the stock price higher.

Risks

• The stock options may not be valuable if the company's stock price does not increase.
• The performance-based vesting of 75,000 stock options may not be achieved if the stock price does not reach the $20 target.

Future Outlook

The document does not contain any specific forward-looking statements beyond the vesting schedules of the stock options and restricted stock units.

Industry Context

The granting of stock options and restricted stock units is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• Stock option grants are a standard form of compensation for executives in the biotech industry, often with vesting schedules tied to performance and time.
• The vesting schedule of the options and restricted stock units is typical for executive compensation packages in the biotech sector.
• The performance-based vesting of 75,000 stock options is a common incentive to align executive interests with shareholder value creation.

Stakeholder Impact

• The stock options and restricted stock units may positively impact shareholders by aligning the CFO's interests with the company's success.
• The compensation package is likely to motivate the CFO to contribute to the company's growth and profitability.

Key Dates

Keywords

stock options, restricted stock units, executive compensation, insider trading, SEC Form 4, Verve Therapeutics, Allison Dorval